Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Joe is CEO of Stanford Wealth Management and a retired SVP of Charles Schwab. He served 36 year in active and reserve military service in special operations and the intelligence community. He brings that geopolitical experience and rational systematic perspective to his research and analysis. He is the author of the investment primer "Bringing Home the Gold" and a member of the SA Marketplace.
If you have a $500,000 portfolio ($250,000 for solely mutual funds & ETFs) you may contact Joe for a no-obligation "second opinion" on your current portfolio: email@example.com.
I am a psychologist at the University of Massachusetts/Amherst. I am on our campus’s Institutional Review Board, which must conclude that proposed studies involving human subjects are conducted ethically and are designed well enough so that any risks involved are justified by the likely benefits obtained.
I teach about analytical reasoning, leadership skills, reconciling apparently incompatible positions, designing, implementing, and evaluating policies, and how to critically evaluate competing health claims based on the samples studied and methods of data collection and analysis used.
Most of my investments involve owning medical industry stocks.
JG Investment Research delivers a complete and detailed investment analysis mostly on small and mid-cap companies on Seeking Alpha. We have won several awards, including being named as one of TipRanks' “Top 100” financial bloggers with an average return per recommendation at 25.4%.
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future.
QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net.
Daniel B. Ravicher is a registered patent attorney who frequently consults with investment banks, hedge funds, and individual investors on legal issues that may materially affect the value of publicly traded companies. In addition to private consulting, Mr. Ravicher also regularly publishes articles covering such issues. He is not an investment adviser and the opinions expressed are not legal, financial or any other kind of advice.
In his legal practice, Mr. Ravicher provides transaction and litigation legal services to clients with respect to a wide range of technologies, including pharmaceuticals, biotechnology, software, the Internet, mobile devices, mechanical devices, consumer products and business methods. He represented the successful plaintiffs in the Supreme Court case invalidating patents on human genes and has twice testified before Congress on the topic of patent reform. Repeatedly named one of 'The 50 Most Influential People in IP' by Managing Intellectual Property and named Appellate Lawyer of the Week by the National Law Journal, Mr. Ravicher has appeared as a guest on national television, been quoted in articles by the Wall Street Journal, Bloomberg, the New York Times, the Financial Times and other publications, and spoken at dozens of national and international conferences on issues relating to patent and technology law.
Mr. Ravicher received his law degree from the University of Virginia School of Law, where he was the Franklin O'Blechman Scholar of his class, a Mortimer Caplin Public Service Award recipient and an Editor of the Virginia Journal of Law and Technology, and his bachelors degree in materials science magna cum laude with University Honors from the University of South Florida. He is admitted to the United States Supreme Court, the Courts of Appeals for the Federal, 2nd and 11th Circuits, the District Courts for the Southern and Eastern Districts of New York and the Southern and Middle Districts of Florida, the States of New York and Florida, and the United States Patent and Trademark Office.